Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.

Results show that the correlation between PADI2 and HER2/ERBB2 overexpression is highly significant across the luminal, basal-NM (non-malignant), and claudin-low cell lines (rho = 0.828, p = 2.2 × 10 -16 ) (Figure 3 ).

also in 132,142 other papers